Atara Biotherapeutics (ATRA) EBT Margin (2021 - 2026)
Atara Biotherapeutics (ATRA) posted EBT Margin of 803.29% for Q1 2026, down 278.17% on a QoQ basis from 212.41% in Q4 2025, and down 84202.0% year-over-year from N/an in Q1 2025.
Atara Biotherapeutics (ATRA) EBT Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics' EBT Margin history runs 6 years deep, the most recent figure standing at 803.29% for Q1 2026.
- Quarterly EBT Margin fell 84202.0% year-over-year to 803.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40.7% (down 3285.0% YoY) and the FY2025 annual result came in at 27.11%, up 9335.0% from the prior year.
- EBT Margin was 803.29% for Q1 2026 at Atara Biotherapeutics, down from 212.41% in the prior quarter.
- Across five years, EBT Margin topped out at 2007.94% in Q4 2023 and bottomed at 43357.93% in Q2 2023.
- A 5-year average of 3792.55% and a median of 119.89% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin slumped 4339373 bps — and 2024, when it surged 4329141 bps.
- Atara Biotherapeutics' EBT Margin stood at 4205.87% in 2022, then jumped by 148 bps to 2007.94% in 2023, then plunged by 102 bps to 38.81% in 2024, then sank by 447 bps to 212.41% in 2025, then sank by 278 bps to 803.29% in 2026.
- Business Quant data shows ATRA's EBT Margin at 803.29% in Q1 2026, 212.41% in Q4 2025, and 123.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | -803.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -803.29% |
| Dec 31, 2025 | -212.41% |
| Sep 30, 2025 | -123.81% |
| Jun 30, 2025 | 13.60% |
| Mar 31, 2025 | 38.73% |
| Dec 31, 2024 | -38.81% |
| Sep 30, 2024 | -54.56% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -115.98% |
| Dec 31, 2023 | 2,007.94% |
| Sep 30, 2023 | -3,456.24% |
| Jun 30, 2023 | -43,357.93% |
| Mar 31, 2023 | -8,455.77% |
| Dec 31, 2022 | -4,205.87% |
| Sep 30, 2022 | -1,885.65% |
| Jun 30, 2022 | 35.80% |
| Dec 31, 2021 | -1,239.07% |
| Sep 30, 2021 | -1,576.61% |
| Jun 30, 2021 | -2,164.78% |
| Mar 31, 2021 | -2,205.38% |